<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018963</url>
  </required_header>
  <id_info>
    <org_study_id>NSPA-2019</org_study_id>
    <nct_id>NCT04018963</nct_id>
  </id_info>
  <brief_title>The Impact of Endoscopic Pituitary Surgery on Nasal Function</brief_title>
  <official_title>Numerical Simulation Analysis of Nasal Physiology After Endoscopic Pituitary Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhebao Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the impact of endoscopic transsphenoidal pituitary
      surgery on nasal function using a numerical simulation and to compare the difference between
      two kinds of transsphenoidal approachese(single nostril approach and bilateral nostril
      approach)．
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuroendoscopic surgery is the first treatment for most pituitary adenoma patients. Because
      transsphenoidal surgery exploits the nasal corridor and paranasal sinuses to reach the skull
      base, sinonasal trauma is a primary source of postoperative morbidity in many of these
      patients. The aim of this study is to determine the impact of endoscopic transsphenoidal
      pituitary surgery on nasal function using a numerical simulation and to compare the
      difference between two kinds of transsphenoidal approachese(single nostril approach and
      bilateral nostril approach)．
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal airway patency.</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed to display geometric parameters of nasal cavity 3 months after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Airflow patterns.</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed. A numerical simulation applying the computational fluid dynamics (CFD) will be performed displaying intranasal airflow patterns 3 months after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature parameter.</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed. A numerical simulation applying the computational fluid dynamics (CFD) will be performed displaying intranasal temperature parameter 3 months after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Humidity parameter.</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed. A numerical simulation applying the computational fluid dynamics (CFD) will be performed displaying intranasal humidity parameter 3 months after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Record the Visual Analogue Scale(VAS) 3 months after surgery. The VAS scale includes six sub-scales: rhinorrhea VAS, rhinobyon VAS，rhinocnesmus VAS, cough VAS, sneezing VAS and olfaction VAS. Each scale has a maximum score of 10 and a minimum score of 0. The total VAS was the average of all sub-scales. Higher values represent a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT Lund-Mackay Score</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Record the CT Lund-Mackay Score 3 months after surgery.The CT Lund-Mackay Score has a maximum score of 24 and a minimum score of 0. Higher values represent a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SNOT-20</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Record the Sino-Nasal Outcome Record the Test-20(SNOT-20) 3 months after surgery. The SNOT-20 has a maximum score of 60 and a minimum score of 0. Higher values represent a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-36</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Record the Medical Outcome Study Short Form 36-items Health survey(SF-36) 3 months after surgery. The SF-36 includes six sub-scales: General Health, Reported Health Transition，Physical Functioning, Role-Physical, Role-Emotional, Social Functioning, Bodily Pain, Vitality and Mental Health. Each scale has a maximum score of 100 and a minimum score of 0. The total score was the average of all sub-scales. Higher values represent a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on Tumor</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Record the tumor volume from enhanced pituitary MRI 3 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal airway patency.</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed to display geometric parameters of nasal cavity 1 week after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airflow patterns.</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed. A numerical simulation applying the computational fluid dynamics (CFD) will be performed displaying intranasal airflow patterns 1 week after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature parameter.</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed. A numerical simulation applying the computational fluid dynamics (CFD) will be performed displaying intranasal temperature parameter 1 week after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humidity parameter.</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>A bilateral model of the human nose on a CT-scan will be reconstructed. A numerical simulation applying the computational fluid dynamics (CFD) will be performed displaying intranasal humidity parameter 1 week after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Record the Medical Outcome Study Short Form 36-items Health survey(SF-36) 1 week after surgery. The SF-36 includes six sub-scales: General Health, Reported Health Transition，Physical Functioning, Role-Physical, Role-Emotional, Social Functioning, Bodily Pain, Vitality and Mental Health. Each scale has a maximum score of 100 and a minimum score of 0. The total score was the average of all sub-scales. Higher values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNOT-20</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Record the Sino-Nasal Outcome Record the Test-20(SNOT-20) 1 week after surgery. The SNOT-20 has a maximum score of 60 and a minimum score of 0. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT Lund-Mackay Score</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Record the CT Lund-Mackay Score 1 week after surgery. The CT Lund-Mackay Score has a maximum score of 24 and a minimum score of 0. Higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Record the Visual Analogue Scale(VAS) 1 week after surgery. The VAS scale includes six sub-scales: rhinorrhea VAS, rhinobyon VAS，rhinocnesmus VAS, cough VAS, sneezing VAS and olfaction VAS. Each scale has a maximum score of 10 and a minimum score of 0. The total VAS was the average of all sub-scales. Higher values represent a better outcome.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pituitary Tumor</condition>
  <condition>Endoscopic Surgery</condition>
  <condition>Quality of Life</condition>
  <condition>Function of Nose</condition>
  <arm_group>
    <arm_group_label>Uninostril group</arm_group_label>
    <description>Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the single nostril approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Binostril group</arm_group_label>
    <description>Subjects will be treated with endoscopic transsphenoidal pituitary surgery with the bilateral nostril approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single nostril approach endoscopic transsphenoidal pituitary surgery</intervention_name>
    <description>Single nostril approach endoscopic transsphenoidal pituitary surgery</description>
    <arm_group_label>Uninostril group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral nostril approach endoscopic transsphenoidal pituitary surgery</intervention_name>
    <description>Bilateral nostril approach endoscopic transsphenoidal pituitary surgery</description>
    <arm_group_label>Binostril group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with endoscopic surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Enhanced MRI shows a pituitary tumor

          2. Endoscopic surgery is required according to the pituitary tumor treatment guidelines.

          3. Karnofsky performance status ≥ 70.

          4. The patient has signed the informed consent.

        Exclusion Criteria:

          1. Patients who have undergone previous transsphenoidal surgery or other nasal surgery.

          2. Patients who had a history of nasal tumors.

          3. Patients who had a history of severe head or face trauma.

          4. Patients with congenital sinus malformation.

          5. Pregnant or lactating women.

          6. Patients with serious systemic diseases without control.

          7. Patients with poor compliance, who cannot implement the program strictly.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhebao Wu, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weiting Gu, Phd</last_name>
    <phone>+86-021-64370045</phone>
    <email>nowaiting1221@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiting Gu</last_name>
      <phone>+8602164370045</phone>
      <phone_ext>+8602164370045</phone_ext>
      <email>nowaiting1221@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Little AS, Kelly D, Milligan J, Griffiths C, Prevedello DM, Carrau RL, Rosseau G, Barkhoudarian G, Otto BA, Jahnke H, Chaloner C, Jelinek KL, Chapple K, White WL. Predictors of sinonasal quality of life and nasal morbidity after fully endoscopic transsphenoidal surgery. J Neurosurg. 2015 Jun;122(6):1458-65. doi: 10.3171/2014.10.JNS141624. Epub 2015 Apr 3.</citation>
    <PMID>25839931</PMID>
  </reference>
  <reference>
    <citation>Tian L, Shang Y, Chen R, Bai R, Chen C, Inthavong K, Tu J. Correlation of regional deposition dosage for inhaled nanoparticles in human and rat olfactory. Part Fibre Toxicol. 2019 Jan 25;16(1):6. doi: 10.1186/s12989-019-0290-8.</citation>
    <PMID>30683122</PMID>
  </reference>
  <reference>
    <citation>McCoul ED, Bedrosian JC, Akselrod O, Anand VK, Schwartz TH. Preservation of multidimensional quality of life after endoscopic pituitary adenoma resection. J Neurosurg. 2015 Sep;123(3):813-20. doi: 10.3171/2014.11.JNS14559. Epub 2015 Jun 5.</citation>
    <PMID>26047408</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhebao Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pituitary tumor</keyword>
  <keyword>Neuroendoscope</keyword>
  <keyword>Surgical approach</keyword>
  <keyword>Computational Fluid Dynamics</keyword>
  <keyword>Numerical simulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

